Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the FDA approval of its biosimilar drug POHERDY, making it the first interchangeable biosimilar of PERJETA in the U.S. market [1] Company Summary - Fuhong Hanlin's stock increased by 4.11%, reaching HKD 67.1, with a trading volume of HKD 31.4021 million [1] - The FDA approved POHERDY, a biosimilar of pertuzumab, allowing it to be used interchangeably with the original product PERJETA, covering all indications previously approved for the original drug in the U.S. [1] - POHERDY is noted as the first biosimilar of pertuzumab in the U.S. and the first interchangeable biosimilar approved for cancer treatment by the FDA [1] - Fuhong Hanlin has submitted applications for HLX11 in China, Europe, and Canada, which have been accepted for review [1] - The company has a total of seven products approved for sale overseas, with four of those approved in the U.S. [1]
港股异动 | 复宏汉霖(02696)现涨超4% POHERDY在美获批上市 可覆盖原研产品所有适应症